Giladi Moshe - Jul 26, 2023 Form 3 Insider Report for NovoCure Ltd (NVCR)

Role
Chief Science Officer
Signature
Steven Robbins, as attorney in fact for Giladi, Moshe
Stock symbol
NVCR
Transactions as of
Jul 26, 2023
Transactions value $
$0
Form type
3
Date filed
12/20/2023, 04:23 PM
Next filing
Feb 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NVCR Ordinary Shares 7.01K Jul 26, 2023 Direct
holding NVCR Restricted Share Units 6.5K Jul 26, 2023 Direct F1
holding NVCR Restricted Share Units 2.98K Jul 26, 2023 Direct F2
holding NVCR Restricted Share Units 1.65K Jul 26, 2023 Direct F3
holding NVCR Restricted Share Units 154 Jul 26, 2023 Direct F4
holding NVCR Restricted Share Units 353 Jul 26, 2023 Direct F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NVCR Stock Options (Right to buy) Jul 26, 2023 Ordinary Shares 1.95K $153.09 Direct F6
holding NVCR Stock Options (Right to buy) Jul 26, 2023 Ordinary Shares 831 $107.73 Direct F7
holding NVCR Stock Options (Right to buy) Jul 26, 2023 Ordinary Shares 7.69K $83.77 Direct F8
holding NVCR Stock Options (Right to buy) Jul 26, 2023 Ordinary Shares 4.35K $80.59 Direct F9
holding NVCR Stock Options (Right to buy) Jul 26, 2023 Ordinary Shares 833 $77.49 Direct F10
holding NVCR Stock Options (Right to buy) Jul 26, 2023 Ordinary Shares 10.8K $76.97 Direct F11
holding NVCR Stock Options (Right to buy) Jul 26, 2023 Ordinary Shares 2.78K $69.37 Direct F12
holding NVCR Stock Options (Right to buy) Jul 26, 2023 Ordinary Shares 2.82K $47.04 Direct F10
holding NVCR Stock Options (Right to buy) Jul 26, 2023 Ordinary Shares 3.45K $21.15 Direct F10
holding NVCR Stock Options (Right to buy) Jul 26, 2023 Ordinary Shares 6.88K $7.15 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted share units that are scheduled to vest in equal installments on February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
F10 Currently exercisable.
F11 Options to buy 10,804 ordinary shares will vest in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
F12 Options to buy 2,779 ordinary shares, 2,085 shares of which are currently exercisable and the remainder will vest on March 3, 2024, subject to the reporting person's continued employment through such date.
F2 Represents restricted share units that are scheduled to vest in equal installments on May 3, 2024 and 2025, subject to the reporting person's continued employment through such dates.
F3 Represents restricted share units that are scheduled to vest in equal installments on March 1, 2024 and 2025, subject to the reporting person's continued employment through such dates.
F4 Represents restricted share units that are scheduled to vest in equal installments on November 2, 2024, subject to the reporting person's continued employment through such date.
F5 Represents restricted share units that are scheduled to vest in equal installments on March 2, 2024, subject to the reporting person's continued employment through such date.
F6 Options to buy 1,951 ordinary shares, 976 shares of which are currently exercisable and the remainder will vest in equal installments on each of March 2, 2024 and 2025, subject to the reporting person's continued employment through such dates.
F7 Options to buy 831 ordinary shares, 416 shares of which are currently exercisable and the remainder will vest in equal installments on each of November 2, 2024 and 2025, subject to the reporting person's continued employment through such dates.
F8 Options to buy 7,693 ordinary shares, 1,924 shares of which are currently exercisable and the remainder will vest in equal installments on each of May 3, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
F9 Options to buy 4,346 ordinary shares, 1,087 shares of which are currently exercisable and the remainder will vest in equal installments on each of March 1, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.